navtemadlin + avelumab

Navtemadlin + avelumab is an investigational combination of two anticancer agents: - **Navtemadlin** is a potent, selective small molecule inhibitor of MDM2, a negative regulator of the tumor suppressor p53. By inhibiting MDM2, navtemadlin reactivates p53, leading to cell cycle arrest, apoptosis, and enhanced killing of tumor cells, especially those with wild-type TP53[1][2][3]. - **Avelumab** is a fully human IgG1 monoclonal antibody targeting the programmed death-ligand 1 (**PD-L1**), blocking the interaction of PD-L1 with PD-1 and restoring T cell-mediated antitumor immune responses. This combination is under early-phase clinical evaluation for the treatment of advanced/metastatic solid tumors and certain hematological malignancies. Both agents have different mechanisms of action: navtemadlin targets tumor-intrinsic survival pathways via the p53 axis, while avelumab modulates adaptive immune responses via checkpoint inhibition.